**Core Concept**
The treatment of neovascular age-related macular degeneration (AMD) involves inhibiting vascular endothelial growth factor (VEGF) to reduce choroidal neovascularization and inflammation. This concept is crucial for understanding the pharmacological principle behind anti-VEGF therapy.

**Why the Correct Answer is Right**
Rociletinib is not the correct answer but the correct answer is not provided in the options. However, a new drug recently approved for treatment of neovascular age-related macular degeneration is Aflibercept. Aflibercept is a recombinant fusion protein that binds to VEGF-A and placental growth factor (PlGF), thereby inhibiting angiogenesis and reducing edema. This mechanism is similar to other anti-VEGF agents like bevacizumab and ranibizumab.

**Why Each Wrong Option is Incorrect**
**Option A:** Not relevant to this question.
**Option B:** Not relevant to this question.
**Option C:** Not relevant to this question.

**Clinical Pearl / High-Yield Fact**
Anti-VEGF therapy has revolutionized the treatment of neovascular AMD by significantly reducing visual loss and improving quality of life for patients. Regular follow-up and frequent injections are essential to maintain efficacy.

**Correct Answer:** Not provided in the options.